Patents Examined by Prema Mertz
  • Interleukin-2 muteins for the expansion of T-regulatory cells
    Patent number: 9580486
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 28, 2017
    Assignee: Amgen Inc.
    Inventors: Marc A. Gavin, Gunasekaran Kannan, Li Li, Joshua T. Pearson, Margaret Karow
  • IL-12 immunoconjugate
    Patent number: 9580485
    Abstract: Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix (ECM) of tissues, particularly tumour neovasculature antigens, for example fibronectin. Use for treating cancer or pathological angiogenesis in a patient.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: February 28, 2017
    Assignee: Philogen S.p.A.
    Inventor: Sarah Wulhfard
  • Sgp130/Fc dimers
    Patent number: 9573989
    Abstract: Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala234-Glu235-Gly236-Ala237. Moreover, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: February 21, 2017
    Assignee: Conaris Research Institute AG
    Inventors: Georg H. Wätzig, Dirk Seegert
  • Carrier immunoglobulins
    Patent number: 9562107
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 7, 2017
    Assignee: AMGEN INC.
    Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, George Doellgast, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
  • Carrier immunoglobulins
    Patent number: 9562108
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 7, 2017
    Assignee: AMGEN INC.
    Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
  • Method of detecting human matrix metalloproteinase 9 using antibodies
    Patent number: 9550836
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: January 24, 2017
    Assignee: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Scott McCauley
  • Compositions and methods of treatment of cancers
    Patent number: 9546196
    Abstract: Described herein are compositions and methods useful to treat cancers. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: January 17, 2017
    Assignee: The University of Toledo
    Inventors: Lirim Shemshedini, Shao-Yong Chen, Changmeng Cai, Chen-Lin Hsieh
  • Aglycosylated Fc-containing polypeptides with cysteine substitutions
    Patent number: 9546203
    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 17, 2017
    Assignee: Amgen Inc.
    Inventor: Gunasekaran Kannan
  • Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
    Patent number: 9539263
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: January 10, 2017
    Assignees: Genentech, Inc., Hoffmann-La Roche, Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Xiaoping Zhang, Kimio Terao, Angelika M. Jahreis
  • Polynucleotide encoding antibody to human IL-3 receptor alpha chain
    Patent number: 9540441
    Abstract: The present invention provides an antibody to human IL-3R? chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3R? chain but does not bind to C domain of the human IL-3R? chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3R? as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3R? is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3R? antibody as an active ingredient.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: January 10, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Tomonori Tawara, Shinichiro Takayanagi, Yoshimasa Inagaki
  • Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
    Patent number: 9539322
    Abstract: An objective of the present invention is to provide novel therapeutic agents for cancer, which have an excellent antitumor effect in cancer patients by enhancing their immune function. The present inventors discovered that the administration of at IL-6 inhibitor and/or gemcitabine or a salt thereof to tumor-bearing organisms yields an excellent antitumor T cell response-enhancing effect, and completed the present invention. In addition, the present inventors discovered that the T cell response-enhancing effect produces an excellent antitumor effect.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: January 10, 2017
    Assignees: National University Corporation Hokkaido University, Chugai Seiyaku Kabushiki Kaisha
    Inventor: Takashi Nishimura
  • Modified IL-13 polypeptides
    Patent number: 9512194
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 6, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • IL-31 monoclonal antibodies
    Patent number: 9512219
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: December 6, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis
    Patent number: 9511086
    Abstract: Methods and compositions for improving immune system function are provided. These methods find particular use in improving immune system function in individuals with a condition in which naïve lymphocytes comprise elevated amounts of DNA double strand breaks (DSB), for example, individuals with Rheumatoid Arthritis, individuals that have received a bone marrow transplant, or elderly individuals, e.g. individuals that are 50 or more years old. Also provided are methods and compositions for screening for novel compounds that will improve immune system function in such individuals.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: December 6, 2016
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Department of Veterans Affairs
    Inventors: Cornelia M. Weyand, Jörg J. Goronzy, Lan Shao
  • Anti-IL-23 antibodies
    Patent number: 9505837
    Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: November 29, 2016
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill M. Giles-Komar, Jinquan Luo, Michael A. Rycyzyn, Raymond Sweet
  • Humanized anti-IL-18 antibodies
    Patent number: 9499617
    Abstract: The present invention discloses humanized anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 22, 2016
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • Human IL-23 antigen binding proteins
    Patent number: 9487580
    Abstract: Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: November 8, 2016
    Assignee: AMGEN INC.
    Inventors: Jennifer E. Towne, Janet D. Cheng, Jason C. O'neill, Yu Zhang, Yu Sun, Heather Cerne, Derek E. Piper, Randal R. Ketchem
  • Method for inhibiting cell death during liver failure by administering a caspase recruitment domain
    Patent number: 9474781
    Abstract: The invention refers to the use of a polynucleotide encoding “apoptosis repressor with caspase recruitment domain” (ARC) or a functional fragment thereof, and/or an ARC polypeptide or a functional fragment thereof for inhibiting cell death of a liver cell, in particular during liver failure.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: October 25, 2016
    Assignee: Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch
    Inventors: Stefan Donath, Junfeng An
  • MPHOSPH1 peptides and vaccines including the same
    Patent number: 9458447
    Abstract: As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: October 4, 2016
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Yusuke Nakamura
  • Method for treatment of diabetic vascular leakage-induced disease using C-peptide
    Patent number: 9457063
    Abstract: Disclosed is a method for the prevention or treatment of vascular leakage-induced diseases and diabetic retinopathy, using C-peptide. Found to prevent extravacular leakage by inhibiting VEGF-induced disassembly of VE-cadherin, C-peptide can be applied to the prevention or treatment of various diabetic complications accompanied by vascular leakage.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: October 4, 2016
    Assignees: KANGWON NATIONAL UNIVERSITY UNIVERSITY-INDUSTRY COOPERATION FOUNDATION, AMOGREENTECH CO., LTD.
    Inventors: Kwon-Soo Ha, Young-Cheol Lim